semaglutide vs tirzepatide
Semaglutide vs tirzepatide, explained.
Semaglutide and tirzepatide are the two most-discussed GLP-1-era medications — and they are not the same. Here's a neutral, factual comparison of what each is, followed by guided care if you want to talk to a provider.
Educational only — not medical advice. Both are prescription medications; a licensed provider makes all clinical decisions. Results vary.
Semaglutide is a GLP-1 receptor agonist — it activates one incretin receptor. Tirzepatide is a dual agonist that activates two receptors, GIP and GLP-1. Both are prescription medications studied in large clinical programs for glucose control and weight management. Which fits a given person is a clinical decision for a licensed provider; results vary.
The short version
The core difference is how many incretin receptors each medication targets. Semaglutide is a single-receptor GLP-1 agonist. Tirzepatide is a first-in-class dual agonist that activates both the GIP and the GLP-1 receptors with one molecule. Both have been studied across large randomized clinical trial programs. They are prescription medications, so the right choice for any individual belongs with a licensed provider.
Side by side
| Attribute | Semaglutide | Tirzepatide | |
|---|---|---|---|
| Drug class | GLP-1 receptor agonist | Dual GIP / GLP-1 receptor agonist | |
| Receptors targeted | One (GLP-1) | Two (GIP and GLP-1) | |
| How it works | Acts on the GLP-1 incretin pathway | Acts on both the GIP and GLP-1 incretin pathways | |
| Typical route | Subcutaneous; an oral form also exists | Subcutaneous | |
| Dosing cadence | Once weekly | Once weekly | |
| Studied for | Glucose control and weight management | Glucose control and weight management |
What to keep in mind
- Both are prescription medications — a licensed provider decides what is appropriate
- They differ in mechanism, not just branding
- Individual responses vary, and so do side-effect profiles
- This page is educational and does not recommend one over the other
Get started
Want to discuss options with a provider? We'll point you to the right first step.
Frequently asked
Is one better than the other?+
There is no single answer — they work differently and suit different people. A licensed provider can assess your situation. PepEasy is educational and does not recommend one over the other.
What is the main difference?+
Semaglutide targets one incretin receptor (GLP-1); tirzepatide targets two (GIP and GLP-1). They are different drug classes.
Can PepEasy help me decide?+
PepEasy connects you with independent licensed providers and gives you tools to track your plan. The clinical decision is always your provider's.
Everything peptides, made easy.
Join PepEasy and get the tools, the knowledge, and the care — in one place.
Explore more